

Sun Pharmaceutical Industries Ltd.,
10th Floor, Indus Tower,
Marol Bhayandur Road,
Bandra (East), Mumbai 400 051 India
Tel: 022-66455645
Fax: 022-66455645



29 February 2012.

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sirs,

Sub: Press Release

We are pleased to enclose herewith a Press Release announcing USFDA approval received for generic version of Zyprexa Zydys® tablets, which we shall be releasing after faxing this letter to you. This is for your information and record.

Thanking you,

Yours faithfully,
For Sun Pharmaceutical Industries Ltd

A handwritten signature in black ink, appearing to read "A. I. Bhuta".

Ashok I. Bhuta
Compliance Officer

Encl: as above

Sun Pharmaceutical Industries Ltd.
 Sun Pharmaceutical Estate
 Sunphar Plaza Road
 Plot of 1000, Marolli 400, 1000 road
 Mumbai - 400 029
 India
 Tel: +91 22 6645 5600
 Fax: +91 22 6645 5601



FOR IMMEDIATE RELEASE

Sun Pharma announces USFDA approval for generic Zyprexa Zydis® tablets

Mumbai, February 29, 2012: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) announced that USFDA has granted an approval for its Abbreviated New Drug Application (ANDA) for generic version of Zyprexa Zydis®, Olanzapine ODT, 5 mg, 10 mg, 15 mg and 20 mg.

These generic Olanzapine Orally Disintegrating tablets, 5 mg, 10 mg, 15 mg and 20 mg are therapeutic equivalents of Eli Lilly's Zyprexa Zydis® tablets. Olanzapine Orally Disintegrating tablets have annual sale of approximately \$ 360 million in the US.

Olanzapine OD tablets are indicated for the treatment of schizophrenia, bipolar I disorder (manic or mixed episodes).

Zyprexa Zydis® is a registered trademark of Eli Lilly & Co.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, nephrology, gastroenterology, ophthalmology and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

Uday Baldota
 Tel +91 22 6645 5645, Xtn 605
 Tel Direct +91 22 66455605
 Mobile +91 98670 10529
 E mail uday.baldota@sunpharma.com

Mira Desai
 Tel +91 22 6645 5645, Xtn 606
 Tel Direct +91 22 66455606
 Mobile +91 98219 23797
 E mail mira.desai@sunpharma.com